Clinical Trials
6 trialsNCT03039114 2025-08-21
Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Incyte Corporation
Phase 1 Completed
NCT03424122 2025-08-21
INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
Incyte Corporation
Phase 1 Completed
NCT03126019 2025-03-14
CITADEL-203
Incyte Corporation
Phase 2 Completed
NCT04434937 2024-10-23
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
Incyte Corporation
Phase 2 Completed
NCT04298879 2024-06-05
IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2 Completed
NCT03314922 2023-08-14
A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)
Incyte Corporation
Phase 1 Completed